GSK Reports on Q4 2025 Pipeline Assets and Clinical Trials

**GSK plc has provided an update on its drug development and clinical trial progress in its Q4 2025 Pipeline Assets and Clinical Trials report. The company is actively monitoring 58 potential new vaccines and medicines across different development phases, covering respiratory, immunology, inflammation, oncology, and infectious diseases.

The report highlights several drug candidates in various stages of development. In Phase III, efimosfermin alfa and bepirovirsen are noted, targeting respiratory, immunology, and inflammation. In oncology, Jemperli (dostarlimab) continues its development, and for infectious diseases, tebipenem pivoxil and Bexsero (meningococcal B vaccine) are mentioned.

Numerous compounds are undergoing Phase II clinical trials. These include Benlysta (belimumab) for autoimmune diseases, GSK4532990 for MASH (metabolic dysfunction-associated steatohepatitis), and GSK5784283 for asthma. In the oncology segment, momelotinib is advancing for myelodysplastic syndrome. The report also lists several candidates related to HIV treatment and tuberculosis in various development stages.

GSK's report offers a comprehensive view of its extensive and diverse drug development pipeline. The company continues to invest in identifying novel therapeutic solutions for significant global health challenges, aiming to enhance treatments and improve patient outcomes.